UGT2B17 and prostate cancer: This observation is supported by the detection of two glucuronide derivatives of sphingosine by mass spectrometry and their increased formation in the UGT2B17-deficient prostate cancer LAPC4 cells expressing UGT2B28 over control cells (Fig. 4e and Supplementary Fig. S1E).